Testing whether genetic scores can guide beta-blocker use in heart failure
Tests a beta-blocker heart medicine in adults with heart failure and mildly reduced pumping strength.
Plain-language title generated from the registry record
Registry title: UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
Key facts
- Where
- Detroit, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 89 years old?
Source: NCT07054489, who can take part
Where in United States
- Henry Ford HealthDetroit, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- David Lanfear
- Trial code
- NCT07054489
- Record updated
- 7 July 2026
- Original description
This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.Read full original descriptionShow less
Using Polygenic Scores to Guide Beta-blocker Therapy for Heart Failure With Mildly Reduced Ejection Fraction
This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.
Inclusion: Age 18-89 years; Ejection Fraction (EF) >40% and =<50% by any modality within 1 year (must be most recent); Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP>35 ng/L or NTproBNP >125 ng/L at any time; Expected ability to fully participate in study (can tolerate study processes, no long travel).
Exclusion: Previous documented EF =< 35%; Currently on BB =>25% target dose; MI/ PCI or other cardiac surgery within 90 days prior to enrollment or planned in the future; Uncontrolled hypertension (systolic BP > 180 at enrollment); Systolic BP < 100 or heart rate <70; Current cancer requiring active treatment; Heart transplant or LVAD or expected in the next year; Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina); Unable to provide informed consent; Has contraindications to all BB or intolerance to metoprolol; Life expectancy < 1 year for any reason; Dialysis dependence or ESRD; If PI decides for any reason participation in trial is not in best interest of the patient; Has a contraindication to completing MRI procedures.